Precision System Science Co.,Ltd. (7707)

Price history

¥207Latest-58.4%

Drag across the chart to measure the move between two points.Delayed 15 minutes · monthly closing basis

Business overview

Precision System Science is an ODM-focused corporate group engaged in the development, manufacture and sale of laboratory automation systems, clinical testing equipment, reagents and consumables for the bioscience sector. The group has a global presence, including through its European subsidiary. Sales of equipment, reagents and consumables increased as sales of genetic testing equipment using the PSS platform expanded. Precision System Science Europe GmbH, based in Düsseldorf, Germany, handles sales and services as the group’s European contact point. The group has Precision System Science Europe GmbH as a consolidated subsidiary and エヌピーエス㈱ as an equity-method affiliate. The ownership ratio in エヌピーエス㈱ declined following a third-party allotment capital increase dated 30 September 2025, and its reagent manufacturing and consumables manufacturing operations were transferred to Quaero through an absorption-type company split.

Recurring subjects

No threads yetThis company's filings have not been read yet. We are adding them progressively.

Companies sharing a theme

Documents

See all timely disclosures See all statutory filings

News

See all news

Key numbersShowing 8 of 19

PER

14.82How many years of earnings it would take to buy the stock. The market average is generally considered to be around 15.

PBR

1.43How many times the company's net assets? Around 1x is generally considered a benchmark.

ROE

9.6%Earning power. A figure above 10% is generally considered good.

Dividend yield

0.0%The annual dividend as a percentage of the share price.

Market capitalization

¥5.8bnShare price × number of shares. The value of the entire company.

Equity ratio

69.9%The proportion of assets funded by money that does not have to be repaid.

Operating margin

3.9%The percentage of revenue remaining from the company’s core business.

Revenue growth (3 years)

-0.4%The average annual growth in sales over the past three years.

What to watch next

大館試薬センター第二工場の稼働率向上と製造原価低減が、売上総利益率/営業利益率に波及しているか（四半期ごとの確認）

The coming quarters (next earnings announcement)Impact HighLikelihood Medium

PSSプラットフォーム（核酸抽出試薬と装置の連動）による装置・試薬・消耗品の同時伸長の継続

2026年度通期に向けてImpact MediumLikelihood Medium

ELITechGroup向けODM供給の売上構成（約76%級）の維持/変動、契約条件の実務面の更新有無

決算および契約運用のタイミング次第（継続監視）Impact HighLikelihood High

復配（2026年期末配当 1株2円）後の配当方針（利益水準とキャッシュ創出）との整合

次期株主還元方針の開示・次回総会Impact MediumLikelihood Medium

NPS→Quaeroへの吸収分割/持分法移行（連結範囲変動を含む）後の、供給安定性と収益認識の変化

直近実行直後〜今後数四半期Impact MediumLikelihood Medium

What to watch next

Who owns itTop holders total 31.2%

Listed holders 31.2%Everyone else 68.8%

Tajima Shuji (田島秀二)16.77%

有限会社ユニテック4.36%

SBI SECURITIES CO., LTD.2.96%

Seita Daisuke (清板大亮)2.41%

楽天証券株式会社1.39%

新井渉1.30%

小玉博之0.51%

Ito Kenta (伊藤健太)0.51%

2 other listed holders0.96%

Who owns it
Holder	Ownership (%)
Tajima Shuji (田島秀二)	16.77
有限会社ユニテック	4.36
SBI SECURITIES CO., LTD.	2.96
Seita Daisuke (清板大亮)	2.41
楽天証券株式会社	1.39
新井渉	1.30
小玉博之	0.51
Ito Kenta (伊藤健太)	0.51
2 other listed holders	0.96

This company's documents

Filings

Timely disclosures

Threads